Tobacco/Nicotine Use Disorder (TUD)
Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.
Key Insights
- 1
Research suggests that psychedelics like ayahuasca have shown promise in significantly reducing tobacco use among participants in clinical studies.
- 2
Ibogaine has been noted for its unique ability to mitigate withdrawal symptoms, providing an alternative pathway for nicotine cessation.
- 3
Emerging findings indicate that psychedelics can potentially reset addictive pathways in the brain, offering new hope for those struggling with tobacco addiction.
What is Tobacco/Nicotine Use Disorder (TUD)?
Tobacco Use Disorder (TUD) is characterised by an addictive reliance on nicotine, leading to compulsive tobacco use despite harmful consequences. It is classified as a substance use disorder in the DSM-5.
The pathophysiology involves neuroadaptation within the brain's reward circuitry, particularly the mesolimbic dopamine system. Nicotine reinforces behaviours associated with tobacco consumption through the stimulation of nicotinic acetylcholine receptors.
Symptoms of TUD can include cravings, withdrawal symptoms, and unsuccessful attempts to quit. Behavioral aspects include increased consumption in social settings and the development of tolerance.
Chronic tobacco use is associated with a range of adverse health effects, including cardiovascular disease, respiratory issues, and various types of cancer.
Current Treatments
Standard treatments for TUD include behavioural therapy, nicotine replacement therapies (NRTs) such as patches and gums, and prescription medications like varenicline and bupropion aimed at reducing cravings and withdrawal symptoms.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Tobacco/Nicotine Use Disorder (TUD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ayahuasca Efficacy shown in clinical studies pointing towards significant reductions in tobacco use. | Large | Moderate | Consistent |
| Ibogaine Demonstrated ability to alleviate withdrawal symptoms commonly associated with nicotine dependence. | Medium | Moderate | Consistent |
| Psilocybin Early-stage studies suggest potential for tobacco cessation, but further research is required. | Small | Low | Inconsistent |
Ayahuasca and Tobacco/Nicotine Use Disorder (TUD)
Ayahuasca, a traditional Amazonian brew, contains DMT and harmaline, which may help in tackling addiction by providing profound emotional insights and facilitating introspection. Users have reported decreased cravings and a re-evaluation of their relationship with tobacco, potentially offering a path towards cessation through a shift in mindset.
Clinical Outlook
The future of psychedelic treatment in Tobacco Use Disorder appears promising, with ongoing research into various compounds suggesting that they may provide essential support in achieving long-term cessation. Continued clinical trials and patient studies will better elucidate the efficacy and safety profiles of these substances in relation to TUD.
Industrial Landscape
Key industry players include major research institutions like the Beckley Foundation, the Multidisciplinary Association for Psychedelic Studies (MAPS), and various universities that are conducting psychedelics research globally.
Quick Indicators
Related Topics
Organisations
Search →National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
New York University
The Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Beckley Med Foundation
Fundación Beckley Med is a Barcelona-based psychedelic research and education organisation, partnered with the UK's Beckley Foundation, that funds and disseminates psychedelic-assisted therapy studies and provides professional training through institutional affiliations with MAPS, Grof Legacy, and CIIS. It collaborated with CITA Clinic to deliver experimental ketamine treatment to patients with treatment-resistant depression in Spain.
Medical University of Gdansk
The Medical University of Gdańsk is Poland's leading academic medical institution, with its Department of Psychiatry running one of the country's most active research programs on ketamine and esketamine for treatment-resistant depression and bipolar disorder.
University of Alabama at Birmingham
Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.
Wake Forest University Health Sciences
Wake Forest University School of Medicine and its clinical affiliate Atrium Health Wake Forest Baptist form a comprehensive academic health sciences enterprise in Winston-Salem, North Carolina. The institution conducts extensive clinical and translational research in psychiatry, neuroscience, addiction medicine, and novel therapeutic approaches, including studies on psychedelic-assisted treatment.
People
Search →Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
Adam Winstock
Professor of Addiction Medicine; Consultant Psychiatrist and Founder/Director of Global Drug Survey
A leading figure in global survey-based research on psychedelics, club drugs, and substance use patterns, with widely cited work informing harm reduction and public health.
Thomas Swift
Assistant Professor in Chemistry at the University of Bradford
He is a coauthor on several qualitative psychedelic-therapy papers that help characterize patient experience, insight, and therapeutic mechanisms in psilocybin and MDMA-assisted treatment.
Ignacio Carrera
Assistant Professor in Organic Chemistry at the Universidad de la República (Facultad de Química)
He is a Uruguayan chemist central to interdisciplinary psychedelic research in Uruguay, with publications on ayahuasca chemistry and ibogaine’s neuropharmacology.
Michael Mithoefer
Senior Medical Director for Medical Affairs at MAPS PBC
Conducted the first FDA-approved clinical trial of MDMA-assisted therapy for PTSD.
Michael Bogenschutz
Professor of Psychiatry
A leading clinician-researcher who has advanced the clinical development of psilocybin-assisted psychotherapy for alcohol use disorder and contributed foundational psychotherapeutic models and clinical trial methodology in modern psychedelic medicine.
Peter Hendricks
Professor of Health Behaviour and Psychedelic Research
Noted for rigorous population‑level epidemiological analyses elucidating associations between classic psychedelic use and mental and physical health outcomes, and for advancing research on microdosing and adverse psychological responses.
Luiz Tófoli
Professor in the Department of Psychiatry, Faculty of Medical Sciences, UNICAMP
Notable for empirical and methodological contributions to the study of ayahuasca, ibogaine and early-stage psychedelic-assisted therapies in Brazil, including survey research on adverse effects and pilot clinical work with MDMA-assisted psychotherapy.
Connected Evidence
The latest clinical data and verified academic findings associated with Tobacco/Nicotine Use Disorder (TUD).